As respiratory diseases continue to pose a global health burden, 2025 is shaping up to be a pivotal year for lung disease therapeutics. From breakthrough biologics targeting chronic obstructive pulmonary disease (COPD) to first-in-class drugs for pulmonary arterial hypertension (PAH) and novel anti-inflammatory inhalants, the respiratory drug market is seeing renewed innovation and expanding indications. […]